Follow the glow
Kurt Krause
University of Otago, New Zealand
Published April 29, 2022
By great luck, the laboratory of Kurt Krause, University of Otago, Dunedin, New Zealand is only an eight-minute drive to a waterfall on Nicols Creek famous for an abundance of native glowworms.
A major tourist attraction, glowworms create a starry night effect in wet places—caves, damp areas of forests, and by streams. Glowworms are not actually worms. They are the larvae of fungus gnats that feed on other insects. They snare prey by secreting a curtain of sticky fishing lines with watery beads that they illuminate with blue-green light to attract insects.
The glowworm proximity sparked new life into a side project on the biology of bioluminescence. Researchers in the Krause lab discovered the enzyme that produces the glow—a luciferase related to the one that gives fireflies their green- gold flash (Scientific Reports, 2018). But the glowworm luciferase works with a structurally distinct luciferin molecular partner.
“That has potential ramifications for being a biotechnology tool, but mostly it’s just kind of a cool ‘wow, why does the glow worm glow’ thing,” Krause says. “I've been a part of some cool stuff, just by saying, ‘Yes, okay, let's give it a go.’”
A native Texan, Krause is an infectious diseases physician who discovered structural biology in medical school and eventually became a fulltime scientist. Most of his lab’s research focuses on proteins and enzymes important in diseases spread by bacteria and viruses, such as tuberculosis and coronavirus.
Krause was born in El Paso to parents who married during World War II. His dad was in the U.S. Air Force, so the family moved around when he was growing up. Home videos show Krause’s first major road trip three months after he was born. His mom and dad loaded him, his two brothers, and a Siamese cat named Sissy into a four-door Nash Rambler sedan and drove on a two-lane highway to their new home at the Elmendorf Air Force Base in Anchorage, Alaska.
Later they lived at several bases in Texas, eventually settling in San Antonio where Krause finished high school. He had become interested in science and sped through his college chemistry major, earning a BA by age 19. He played piano seriously and studied the pipe organ, achieving a milestone with J.S. Bach’s Toccata and Fugue in D Minor. A fist fight derailed his keyboard aspirations for a while, but the other guy became a multimillionaire oil and gas tycoon who later funded some of Krause’s research.
Medical school seemed the next logical next step for someone interested in how the human body works, Krause reasoned.
Baylor College of Medicine in Houston was an old-fashioned school, featuring biochemistry, physiology, anatomy, embryology, molecular biology and other courses instead of the case-based curriculum popular today.
“I felt like the whole world opened up in front of me,” he says. “I was seeing protein structures that were just beginning to get solved at that time. It was certainly still quite difficult. And I thought, if you had a protein structure, you had the potential to design a drug. You could design something very specific and very active that presumably wouldn't bind to other proteins.”
By the time he finished medical school, he had decided to get a PhD in protein structure and function. Baylor didn’t offer protein crystallography, so Krause bought an airline pass good for a month or two of unlimited domestic travel. He visited more than one dozen schools across the country, from Stanford to Yale, meeting researchers whose names were familiar from his textbooks.
Choosing Harvard, it was William Lipscomb, a Nobel Laureate, who won over Krause with his teaching style in a class on enzymes.
It was the early 1980s, but Lipscomb had devised a way to display three- dimensional molecular images in the middle of the classroom using two 35- millimeter slide projectors with different polarizing filters. He handed out 3D glasses to students and then walked into the projected image to point out the active site and other features.
“It was awesome. He was so far ahead of his time,” says Krause. “So I joined the lab. It was just the best experience of my life.” “The Colonel,” as he was known to friends and colleagues, had an open-door policy and regular hours (10 am to 4 pm, then 7-10 pm), but he was busy during the day. Krause learned to be at the lab during the evening hours, when The Colonel had time to chat.
The lab was involved in early drug discovery based on the high-resolution structure they had solved of the enzyme carboxypeptidase. Most of Krause’s thesis work was on a larger enzyme, dodecameric aspartate transcarbamoylase.
The glowworm project also traces back to his graduate student days. In search of an interesting collaborative project, Lipscomb asked Krause to be his emissary to the nearby bioluminescence lab of Woody Hastings, igniting a longstanding interest.
After his thesis and a short postdoc, Krause returned to patient care at Baylor, first for a residency in internal medicine and then for his first faculty job. Crystals were growing in the lab, but he had no X-ray equipment. Down the street, J. Andrew McCammon, a University of Houston faculty member, suggested Krause move his crystallography lab there.
With dual academic appointments over the next decade, Krause stepped up the crystallography research while also working part time as a general internal medicine physician. His first structure was the extracellular nuclease that augmented the pathogenicity of Serratia marcescens (Nature Structural Biology, 1994). They quickly obtained crystals that diffracted to 0.88Å, among the highest for that size protein.
The nuclease crystals were so well ordered they diffracted well below 1.0 angstrom. “We could see individual hydrogen atoms,” he says. “We had big plans for trying to use this structure as a way to compare bond-lengths and angles for amino acids within proteins to those from the Cambridge database, which were solved in isolation. But NIH, our initial funder, was not so keen.”
More NIH funding came with a shift to infectious diseases work on antibiotic discovery. The initial focus was on alanine racemase “which everyone hoped would be the perfect drug target. Made sense because D-alanine makes up part of the bacterial cell wall,” he says, “And we don't have any D-alanine in us. If you block a bacteria's ability to make D-alanine, you'll kill it. But if you end up inhibiting the ability for people to produce D-alanine, it's not a problem.”
Unfortunately, they eventually discovered the active site, a tight dimer, was virtually inaccessible to potential drugs.
As his interest in infectious diseases grew, Krause added a clinical fellowship in infectious disease at Baylor to his schedule. It was a pivotal experience.
Most of his early patients had advanced AIDS and died within 6 months. With no proven therapeutics to fight HIV, pandemic deniers challenged the viral origin of the disease, and desperate people promoted useless and dangerous alternative treatments. But soon, a series of controlled clinical trials showed that certain medicines were effective and even more so when used in a triple cocktail.
“It was this incredible experience of seeing all these people dying, transitioning as therapies improved, to almost nobody dying,” he says. “All of a sudden, people had zero viral loads and essentially a normal life expectancy. It was like the scientific method had been validated. Now patients were telling me, ‘Hey, I'm looking for a new job, and I want to get married. And I want to have kids.’ Gamechanger. And it set me up for the more recent [coronavirus] pandemic. I knew that if the research was carried out properly, the proper therapies would be found.”
It was both incredible and unsustainable. Krause was working in the lab during the day and his clinical duties had expanded to include both night HIV clinics and weekend hospital work.
He was negotiating a job offer to set up a new emerging infectious disease center in Ohio when University of Otago called about a biochemistry chair position. On a visit to New Zealand, he found a department staffed with impressive pedigrees from top institutions, some overlapping Krause’s academic family tree. They promised him X-ray equipment. He moved into his new lab in December 2005.
“Our work now is drug discovery and infectious diseases, antiviral and antibacterial, with a side theme in bioluminescence,” he says.
Meanwhile, about halfway through the alanine racemase project, a friend at Chiron, a U.S. biotechnology company acquired by Novartis, called Krause and told him he should be working on glutamate racemase, which has a much more open active site. It turned out that the company was closing down its antibiotic making projects completely. His friend thought the science should continue somewhere.
The tip initially culminated in the structural determination of glutamate racemase from Mycobacterium tuberculosis and Mycobacterium smegmatis (Biochemical Journal, 2016). Now, the Krause lab is looking for targeted inhibitors as new antibiotic candidates. “Every enzyme has its own secret issues,” he says. “The active site of glutamate racemase is open, but still problematic in terms of drug design, but I think we’re found ways around that.”
A second drug development project involves BD oxidase. The project has its origins in a 2015 research sabbatical. Krause visited the Frankfurt, Germany, lab of Hartmut Michel, a Nobel Laureate he had met as a graduate student for Lipscomb.
There, Krause worked with Michel’s postdocs on modern membrane protein structural research using cryo-EM. That’s where Krause learned about BD oxidase. Ironically, he discovered that the main research on this protein was being done in New Zealand by Greg Cook, who was already collaborating with Krause on the glutamate project. “He’s just down the hall from me, and I didn’t know he was doing anything on this protein,” Krause says. “I heard about it by going to Germany!”
The collaborators secured a grant and determined the structure (Nature Communications, 2021). “BD oxidase may be the perfect drug target for tuberculosis (TB) drug design,” Krause says. “Now we're trying to see if we can turn this new structure into new drugs for infected patients.”
On his sabbatical, he also was hosted by the Boston lab of Eric Rubin, a tuberculosis researcher at the Harvard School of Public Health and editor of the New England Journal of Medicine. There Krause was first exposed to SBGrid, whose offices are nearby. He embraced the service as a painless solution to the fatigue of maintaining up-to-date software and computing equipment to support structural biology research.
In 2018, Krause invited SBGrid’s Piotr Sliz and Jason Key to an international structural biology meeting in Auckland. Since then, the Krause laboratory has become host for a fledgling hub for SBGrid to expand its services into the Australia-Asia-South Pacific region. The lab has funding and a dedicated SBGrid outreach postdoc.
By now, Krause may know more words in Te Reo, the language spoken by the indigenous Māori people of New Zealand, than the smattering of everyday Spanish he spoke growing up in Texas.
In fact, Krause worked some of the new vocabulary into a recent grant proposal for a research project in bioluminescence. If pressed for a favorite Māori word, he would choose “titiwai,” the name for glowworms, which means “projected over water.”
“Our titiwai work strives to have a focus on kaitiakitanga (guardianship and protection), whanaungatanga (relationships and belonging) and manakitanga (kindness and support),” he explains. The three guidelines also happen to be the mantra of the famous Waitomo Glowworm Caves, whose Māori guardian, or kaitiaki, will perform the same role for the Krause lab.
-Carol Cruzan Morton
Other tales
-
![]()
The Shapes of Energy
Luke Chao
Published 12 December 2024
![]()
Predicting Proteins
Jens Meiler
Published 25 November 2024
-
![]()
Death Metal
Steven Damo
Published 28 April 2024
![]()
Context Matters
Bing Chen
Published 30 January 2024
-
![]()
The Crystal Whisperer
Sarah Bowman
Published 29 November 2023
![]()
Data in Motion
Nozomi Ando
Published 29 September 2023
-
![]()
The Monstrous Maw
André Hoelz
Published 28 June 2023
![]()
Second Takes
Andrea Thorn
Published 28 February 2023
-
![]()
Radical reactions
Yvain Nicolet
Published 31 January 2023
![]()
Floppy Physics
Eva Nogales
Published 30 November 2022
-
![]()
Structure of Equity
Jamaine Davis
Published 28 September 2022
![]()
Life and Death of a Cell
Evris Gavathiotis
Published 28 July 2022
-
![]()
Follow the glow
Kurt Krause
Published 29 April 2022
![]()
Resolution solutions
Willy Wriggers
Published 25 February 2022
-
![]()
Of enzymes and membranes
Ming Zhou
Published 28 October 2021
![]()
Step-by-step
Gabrielle Rudenko
Published 26 September 2021
-
![]()
Moving muscle
Montserrat Samso
Published 26 July 2021
![]()
Particle catcher
Stefan Raunser
Published 28 June 2021
-
![]()
Designer drugs
Ho Leung Ng
Published 25 February 2021
![]()
Right place, right time
Ernesto Fuentes
Published 29 January 2021
-
![]()
Shape-shifting secrets of membranes
James Hurley
Published 27 November 2020
![]()
Enzymatic action
Cynthia Wolberger
Published 28 September 2020
-
![]()
Rules of motion
Priyamvada Acharya
Published 31 July 2020
![]()
Cosmic Squared
Michael Cianfrocco
Published 27 June 2020
-
![]()
Kaps are Cool
Yuh Min Chook
Published 28 April 2020
![]()
Spiraling into focus
Carsten Sachse
Published 29 March 2020
-
![]()
Seeing cilia
Alan Brown
Published 27 February 2020
![]()
For the Love of EM
Guy Schoehn
Published 27 January 2020
-
![]()
Protein Puddles
Michael Rosen
Published 16 December 2019
![]()
Changing channels
Daniel Minor Jr.
Published 27 September 2019
-
![]()
Listening Tips
Marcos Sotomayor
Published 30 July 2019
![]()
Beyond Cool
Published 31 May 2019
-
![]()
Hao Wu
A Higher Order
Published 30 May 2019
![]()
Aye Aye Captain
Alexandre Bonvin
Published 29 April 2019
-
![]()
The PARP Family Family
John Pascal
Published 28 February 2019
![]()
Frame by frame
Nikolaus Grigorieff
Published 28 January 2019
-
![]()
Predicting Success
Bil Clemons
Published 18 December 2018
![]()
Curiouser and Curiouser
Ramaswamy Subramanian
Published 27 November 2018
-
![]()
Rely on This
Sjors Scheres
Published 26 October 2018
![]()
Proteins out of bounds
Gerhard Wagner
Published 27 September 2018
-
![]()
Hiding in plain sight
Gaya Amarasinghe
Published 27 July 2018
![]()
Jumping Genes
Orsolya Barabas
Published 27 June 2018
-
![]()
Data Whisperer
Karolin Luger
Published 30 May 2018
![]()
Flipping the Switch
Jacqueline Cherfils
Published 27 April 2018
-
![]()
Tooling Around
Andrew Kruse
Published 29 March 2018
![]()
Comings and Goings
Tom Rapoport, Ph.D.
Published 23 February 2018
-
![]()
Transcriptional Rhythm
Seth Darst
Published 27 January 2018
![]()
The Language of Gene Regulation
Daniel Panne
Published 21 November 2017
-
![]()
Not Your Average Protein
James Fraser
Published 23 October 2017
![]()
Message Received
Sebastien Granier
Published 24 August 2017
-
![]()
Resistance is Futile
Celia Schiffer
Published 28 July 2017
![]()
Twist of Fate
Leemor Joshua-Tor
Published 28 June 2017
-
![]()
Drug Designer
John Buolamwini
Published 30 May 2017
![]()
Mathematically Minded
James Holton
Published 28 April 2017
-
![]()
Garbage Out
Kay Diederichs
Published 30 March 2017
![]()
Fixer Upper
Brandt Eichman
Published 27 February 2017
-
![]()
Mobilizers
Phoebe Rice
Published 31 January 2017
![]()
Escape Artist
Katya Heldwein
Published 19 December 2016
-
![]()
Nature’s Confectioner
Jochen Zimmer
Published 29 November 2016
![]()
State of Fusion
Jason McLellan
Published 27 October 2016
-
![]()
Here Be Dragons
Brian Fox
Published 28 September 2016
![]()
SBGrid Assumes Ownership of PyMOLWiki
Published 15 September 2016
-
![]()
Pharm Team
Oleg Tsodikov
Published 24 August 2016
![]()
Spiro-Gyra
Alejandro Buschiazzo
Published 27 July 2016
-
![]()
Turning the DIALS
Nicholas Sauter
Published 29 June 2016
![]()
Pipeline Dreams
Bridget Carragher and Clint Potter
Published 26 April 2016
-
![]()
U-Store-It
The SBGrid Data Bank provides an affordable and sustainable way to preserve and share structural biology data
Published 28 March 2016
![]()
Big Questions, Big Answers
Jennifer Doudna
Published 22 February 2016
-
![]()
Not a Structural Biologist
Enrico Di Cera
Published 17 December 2015
![]()
Divide and Conquer
Kevin Corbett
Published 19 November 2015
-
![]()
Computing Cellular Clockworks
Klaus Schulten
Published 23 October 2015
![]()
Trans-Plant
Gang Dong
Published 26 September 2015
-
![]()
Keep on Moving
James Berger
Published 23 August 2015
![]()
Totally Tubular
Antonina Roll-Mecak
Published 27 July 2015
-
![]()
From Disorder, Function
Julie Forman-Kay
Published 29 June 2015
![]()
Into Alignment
Geoff Barton
Published 27 May 2015
-
![]()
Two Labs, Many Methods
Michael Sattler
Published 28 April 2015
![]()
Picture This
Georgios Skiniotis
Published 20 March 2015
-
![]()
Intron Intrigue
Navtej Toor
Published 20 February 2015
![]()
Cut and Paste
Martin Jinek
Published 28 January 2015
-
![]()
Basics and Beyond
Qing Fan
Published 18 December 2014
![]()
Bloodletting and Other Studies
Pedro José Barbosa Pereira
Published 25 November 2014
-
![]()
Wire Models, Wired
A brief history of UCSF Chimera
Published 29 October 2014
![]()
In Search of…New Drugs
Doug Daniels
Published 30 September 2014
-
![]()
An Affinity for Affinity…and Corals
John C. Williams
Published 29 August 2014
![]()
Pete Meyer, Ph.D.
Research Computing Specialist
Published 22 August 2014
-
![]()
Justin O'Connor
Sr. System Administrator
Published 20 August 2014
![]()
Carol Herre
Software Release Engineer
Published 15 August 2014
-
![]()
Elizabeth Dougherty
Science Writer
Published 13 August 2014
![]()
Andrew Morin, Ph.D.
Policy Research Fellow
Published 11 August 2014
-
![]()
Jason Key, Ph.D.
Associate Director of Technology and Innovation
Published 8 August 2014
![]()
Piotr Sliz, Ph.D.
Principal Investigator, SBGrid
Published 1 August 2014
-
![]()
New Kid on the Block
James Chen
Published 29 July 2014
![]()
Membrane Master
Tamir Gonen
Published 30 June 2014
-
![]()
The Natural Bridge
Piotr Sliz
Published 13 June 2014
![]()
Surprise, Surprise
Catherine Drennan
Published 26 April 2014
-
![]()
Gone Viral
Olve Peersen
Published 20 March 2014
![]()
All Who Wander Are Not Lost
Frank Delaglio
Published 24 February 2014
-
![]()
The Raw and the Cooked
Graeme Winter
Published 24 January 2014
![]()
Vacc-elerator
Peter Kwong
Published 17 December 2013
-
![]()
Structural Storyteller
Karin Reinisch
Published 15 November 2013
![]()
The Fixer
Jane Richardson
Published 28 October 2013
-
![]()
Inside the Box
Mishtu Dey
Published 17 September 2013
![]()
Sensing a Change
Brian Crane
Published 16 August 2013
-
![]()
Towards Personalized Oncology
Mark Lemmon
Published 16 July 2013
![]()
Brush with Fame
Yizhi Jane Tao
Published 14 June 2013
-
![]()
Toxic Avenger
Borden Lacy
Published 21 May 2013
![]()
Pushing the Boundaries
Stephen Harrison
Published 22 April 2013
-
![]()
Strength in Numbers
Joseph Ho
Published 18 March 2013
![]()
One Lab, Many Methods
Wesley Sundquist
Published 12 February 2013
-
![]()
Unplanned Pioneer
Tim Stevens
Published 15 January 2013
![]()
From Actin to Action
Emil Pai
Published 11 January 2013
-
![]()
Unstructured
A Brief History of CCP4
Published 12 December 2012
![]()
Stop, Collaborate and Listen
Eleanor Dodson
Published 5 November 2012
-
![]()
X-PLORer
Axel Brunger
Published 1 October 2012
![]()
Share the Wealth
Zbyszek Otwinowski
Published 22 August 2012
-
![]()
Unraveling RNA
Anna Pyle
Published 18 July 2012
![]()
Sharper Image
Pawel Penczek and SPARX
Published 4 June 2012
-
![]()
Creative Copy Cat
Pamela Bjorkman
Published 25 April 2012
![]()
Charm and Diplomacy
Gerard Kleywegt
Published 7 March 2012
-
![]()
From Curiosity to Cure
Marc Kvansakul
Published 13 December 2011
![]()
The Lure of the Sandbox
Paul Emsley and Coot
Published 15 October 2011
-
![]()
Springsteen, Tolkien, Protein
Alwyn Jones and Frodo
Published 17 June 2011
![]()
Structures Solved Simply
Paul Adams and Tom Terwilliger on Phenix
Published 2 June 2011
-
![]()
Escape from the Darkroom
Wolfgang Kabsch and XDS
Published 19 May 2011
![]()
Playing the Odds
Randy Read and Phaser
Published 19 May 2011
-
![]()
Crystallography for Kids
Lynne Howell
Published 17 May 2011
![]()
Better, Faster, Stronger, More
Victor Lamzin and ARP/wARP
Published 17 May 2011
